Sanofi's Leadership Shift: Paul Hudson's Exit Marks Strategy Pivot Amid Vaccine and Dupixent Challenges

Sanofi announced a significant leadership transition on Wednesday, with the board deciding not to renew Paul Hudson’s contract as Chief Executive Officer. Hudson, who has led the pharmaceutical giant for six years since 2019, will depart on February 17, 2026. This decision underscores mounting pressure on the company from multiple fronts—faltering vaccine revenues and challenges in diversifying beyond its blockbuster drug Dupixent.

Paul Hudson’s Tenure: Achievements and Strategic Struggles

When Paul Hudson took the helm in 2019, his mandate was clear: revitalize Sanofi’s flagging drug pipeline and restore investor confidence in the company’s stock price. Under his leadership, the company made progress in several areas, yet struggled with a critical challenge—reducing the company’s heavy reliance on Dupixent, an eczema treatment that has become too dominant in the revenue mix. Despite strong Q4 2025 sales of 4.2 billion euros (up 32.2%), Hudson’s efforts to build a balanced pipeline faced headwinds. As Sanofi’s Chief Financial Officer François-Xavier Roger candidly told Reuters, “We believe that we will not be able to mitigate the impact of the loss of exclusivity of Dupixent as far as sales are concerned. It’s too big to be mitigated.”

Vaccine Portfolio Under Pressure: The Polio Connection and Beyond

The vaccine segment has emerged as another critical pain point during Hudson’s tenure. Fourth-quarter 2025 vaccine sales declined 2.5% to 2 billion euros, highlighting structural challenges in this unit. Among the specific declines, the polio/pertussis/Hib (PPH) vaccine platform—which protects against polio and other childhood diseases—saw sales drop 9.5% to 551 million euros, primarily due to fewer births in key markets including China. Meanwhile, Beyfortus sales fell 14.9% to 686 million euros, though influenza and COVID-19 vaccines showed resilience, rising 31.5% to 575 million euros. These mixed results reveal a vaccine business caught between declining primary demand and evolving market dynamics.

Belén Garijo Takes the Helm with a Mandate for Transformation

Effective April 29, 2026, at the close of Sanofi’s Annual General Meeting, Belén Garijo will become the new Chief Executive Officer. Garijo brings significant pedigree to the role, having served as Chief Executive of Merck KGaA since 2021, making her the first woman to lead a DAX40 company in Germany. Her appointment signals the board’s determination to inject what they describe as “increased rigor” into Sanofi’s strategic execution. Interim Chief Executive Officer Olivier Charmeil, Executive Vice President of General Medicines, will bridge the transition period.

Garijo’s priorities are clearly defined: strengthening R&D productivity and innovation capacity, improving governance, and accelerating the preparation of Sanofi’s future growth platforms. Notably, the company is investing in amlitelimab as a potential successor to Dupixent, with recent clinical data demonstrating robust evidence of its efficacy in treating moderate-to-severe atopic dermatitis in patients aged 12 and older.

Market Response and the Road Ahead

On Thursday premarket trading, Sanofi shares declined 6.25% to $46.17, reflecting investor concerns about the immediate transition and the underlying business challenges. However, Garijo’s track record suggests the company is positioning itself for deeper operational improvements rather than incremental changes. Her tenure at Merck demonstrated an ability to drive innovation and execute complex transformations, qualities Sanofi’s board believes are essential to navigate the coming years of patent expiration and competitive pressures. The appointment marks a clear inflection point: the era of Paul Hudson’s stewardship has concluded, and a new strategic chapter is beginning.